恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究

doi:10.3969/j.issn.1672-5069.2019.06.038

Abstract

Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment[J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.

References

[1] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅥ.
[2] McBride G. Hepatitis B virus-induced liver cancer in Asian Americans:preventable disease. J Natl Cancer Inst,2008,100(8):528-529.
[3] Liang XF,Bi SL,Yang WZ,et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine,2013,27(31 Suppl 9):J21-28.
[4] Chen CH,Lu SN,Hung CH,et al.The role of hepatitis B surface antigen quantification in prediciting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol,2014,61(3):515-522.
[5] Ning Q,Han M,Sun Y,et al.Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:A randomised open-label trial (OSST trial). J Hepatol,2014,61(3):777-784.
[6] Chang TT,Gish RG,de Man R,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med,2006,354:1001-1010.
[7] Lai CL,Shouval D,Lok AS,et al.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med,2006,354:1011-1020.
[8] Heathcote EJ,Marcellin P,Buti M,et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.Gastroenterology,2011,140:132-143.
[9] Rijckborst V,Hansen BE,Ferenci P,et al.Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg negative patients treated with peginterferon alfa-2a. J Hepatol,2012,56(5):1006-10011.
[10] Rijckborst V,Hansen BE,Cakaloglu Y,et al.Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.Hepatology,2010,52(2):454-461.
[11] Thursz M,Yee L,Khakoo S.Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis,2011,31(2):115-127.
[12] Mcphee F,Friborg J.Endogenous IFN in viral hepatitis patients. J Interferon Cytokine Res,2014,34(7):552-556.
[13] Takkenberg RB,Menting S,Beid MG.Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. Methods Mol Biol,2012,903:113-128.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.

Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments